Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
about
Anticancer drug targets: growth factors and growth factor signaling.CHARMM force field parameters for simulation of reactive intermediates in native and thio-substituted ribozymesOligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicingTriggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles.Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.
P2860
Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Toward antisense oligonucleoti ...... ounds in clinical development.
@ast
Toward antisense oligonucleoti ...... ounds in clinical development.
@en
Toward antisense oligonucleoti ...... ounds in clinical development.
@nl
type
label
Toward antisense oligonucleoti ...... ounds in clinical development.
@ast
Toward antisense oligonucleoti ...... ounds in clinical development.
@en
Toward antisense oligonucleoti ...... ounds in clinical development.
@nl
prefLabel
Toward antisense oligonucleoti ...... ounds in clinical development.
@ast
Toward antisense oligonucleoti ...... ounds in clinical development.
@en
Toward antisense oligonucleoti ...... ounds in clinical development.
@nl
P2093
P1476
Toward antisense oligonucleoti ...... pounds in clinical development
@en
P2093
P304
P577
1999-06-01T00:00:00Z